Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.
about
Updates of mTOR inhibitorsmTOR inhibitors in advanced renal cell carcinomaRapamycin and mTOR kinase inhibitorsPotential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathwayTargeting the mTOR signaling network for cancer therapyImmunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantationDifferentiating mTOR inhibitors in renal cell carcinomaPredicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapyARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathwayS9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeletonEverolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenibmTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktSirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium ReportBiomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further ProposalsRapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: a search for biomarkers of sensitivity to treatment.Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer.The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivityRationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinomaPhase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway.Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.Exploiting novel molecular targets in gastrointestinal cancers.Everolimus - a new approach in the treatment of renal cell carcinomaEvaluation of the impact of the cancer therapy everolimus on the central nervous system in miceDaily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinomaPhase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung CancerSafety and efficacy of everolimus in adult patients with neuroendocrine tumors.RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex
P2860
Q24607170-C49D761C-1733-4473-8478-D9EDD04DB22DQ24612127-3DECF1E3-D183-4032-9145-D18C19B97DDDQ24644623-599D1820-6BF9-4F00-8736-3DFBCA6B7998Q24648029-8F93ECD2-C417-4E01-93C4-7518A16B4FD2Q24658334-F0E242A2-6B92-45FB-A9F0-C4247941761EQ26751433-1F653B11-4E86-455A-9E90-B644FDD71144Q26860172-100986E3-D52B-44AF-8B67-03C393CB9D9DQ27851999-1E93C472-876B-4447-B441-45FE971F5FBCQ28079861-1DC4B260-1A0E-4362-8039-7E465A3294E1Q28272830-5A3E1EAB-770A-4468-A3D6-77E6F683DD1EQ28475032-5E7C12A2-7C21-42E6-873F-0D74E91E4D1BQ28765488-291BA643-0546-44DD-9856-0052337DC3B7Q29547767-E895D63B-2743-4742-A80E-45D778896A39Q33376348-3DF7F19E-F3AA-4059-B849-479188B3DCA8Q33382682-2F8C706C-0C81-4833-B772-DB4099B6FB3CQ33383550-06E20380-C873-4FB5-ABF6-BB03CFD8BF02Q33385120-D0738DFE-412E-4419-B117-D3D7BC56BF84Q33407021-D0EC480A-BB4B-44A7-ABDB-74EF0D747FEEQ33414827-70378D3C-CEAC-4A79-97C1-66D59E12D7A0Q33419115-53AA4451-5228-4CA4-853A-F24C597F6FA7Q33760578-F7F81B16-22E8-4D3A-8704-89C2922BFD69Q33903478-60C25BC3-6356-48D6-987F-CA1C46F90E8FQ33947770-29E2F2E8-1421-4338-BA72-CDAB16C01A12Q34036041-49F57358-2D5A-420B-8151-069135955859Q34064359-9B03E089-3B4E-4F52-9436-6DFC1B7E34D5Q34130665-BF4ED800-76D4-4785-BD6F-6ECC416AE87FQ34235680-DBE160C6-B825-4C62-967F-008E079E9345Q34250227-7C0D1C66-7E9A-4913-8A59-B2F8A41FD9F0Q34261603-7F73818F-B551-4FF7-B12F-2CB2D59C836CQ34348318-692B510C-95C4-4011-A0BD-F9F13E183CCDQ34382777-919EF7D0-1027-434A-9793-B2242E616209Q34417931-FE720F30-0B20-43FE-9158-8B452EAFC786Q34600979-78AF7FAA-6719-4EEC-AE9B-8AF2050AF8CEQ34965132-E21E1165-D8D8-4D1D-BD40-40510B977B11Q35135727-5AFDD9FE-5018-4D31-BA54-C35A2DCE7E22Q35142268-ED7225B7-1D49-4725-973D-874258A6D209Q35463464-082CE413-47C8-428A-BEAD-2E202B05D268Q35669138-5DDBE8FF-BD14-4EAD-B26F-6F0B86EEE471Q35832116-1B6F479A-4EAA-4034-B322-811ACF2C6E4CQ35832641-913AB365-06F5-4680-B82B-E2FD3FF0D0A1
P2860
Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Antitumor efficacy of intermit ...... heral blood mononuclear cells.
@en
Antitumor efficacy of intermit ...... heral blood mononuclear cells.
@nl
type
label
Antitumor efficacy of intermit ...... heral blood mononuclear cells.
@en
Antitumor efficacy of intermit ...... heral blood mononuclear cells.
@nl
prefLabel
Antitumor efficacy of intermit ...... heral blood mononuclear cells.
@en
Antitumor efficacy of intermit ...... heral blood mononuclear cells.
@nl
P2093
P1433
P1476
Antitumor efficacy of intermit ...... pheral blood mononuclear cells
@en
P2093
Andreas Marti
Anne Boulay
Barbara Stolz
Christine Stephan
Christoph Heusser
Frederic Zilbermann
Heidi A Lane
Iwan Beuvink
Roland Haller
Sabine Zumstein-Mecker
P304
P356
10.1158/0008-5472.CAN-3554-2
P407
P577
2004-01-01T00:00:00Z